Ebos JM - Search Results

1

The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.

Mastri M, Rosario S, Tracz A, Frink RE, Brekken RA, Ebos JM. Mastri M, et al. Among authors: ebos jm. Curr Drug Targets. 2016;17(15):1747-1754. doi: 10.2174/1389450117666151209123544. Curr Drug Targets. 2016. PMID: 26648063 Free PMC article. Review.

2

Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.

Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS. Shaked Y, et al. Among authors: ebos jm. Curr Cancer Drug Targets. 2005 Nov;5(7):551-9. doi: 10.2174/156800905774574020. Curr Cancer Drug Targets. 2005. PMID: 16305351 Review.

3

Mind the gap: potential for rebounds during antiangiogenic treatment breaks.

Ebos JM, Pili R. Ebos JM, et al. Clin Cancer Res. 2012 Jul 15;18(14):3719-21. doi: 10.1158/1078-0432.CCR-12-1459. Epub 2012 Jun 7. Clin Cancer Res. 2012. PMID: 22679177

4

Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond.

Mittal K, Ebos J, Rini B. Mittal K, et al. Semin Oncol. 2014 Apr;41(2):235-51. doi: 10.1053/j.seminoncol.2014.02.007. Epub 2014 Feb 28. Semin Oncol. 2014. PMID: 24787295 Review.

5

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy.

Tracz A, Mastri M, Lee CR, Pili R, Ebos JM. Tracz A, et al. Among authors: ebos jm. J Vis Exp. 2014 Apr 29;(86):51485. doi: 10.3791/51485. J Vis Exp. 2014. PMID: 24836396 Free PMC article.

6

Classical mathematical models for description and prediction of experimental tumor growth.

Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JM, Hlatky L, Hahnfeldt P. Benzekry S, et al. Among authors: ebos jm. PLoS Comput Biol. 2014 Aug 28;10(8):e1003800. doi: 10.1371/journal.pcbi.1003800. eCollection 2014 Aug. PLoS Comput Biol. 2014. PMID: 25167199 Free PMC article.

7

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Ebos JM, et al. EMBO Mol Med. 2014 Dec;6(12):1561-76. doi: 10.15252/emmm.201403989. EMBO Mol Med. 2014. PMID: 25361689 Free PMC article.

8

Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis.

Ebos JM. Ebos JM. Cancer Res. 2015 Sep 1;75(17):3427-35. doi: 10.1158/0008-5472.CAN-15-0308. Epub 2015 Jul 30. Cancer Res. 2015. PMID: 26229121 Review.

9

Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach.

Benzekry S, Tracz A, Mastri M, Corbelli R, Barbolosi D, Ebos JM. Benzekry S, et al. Among authors: ebos jm. Cancer Res. 2016 Feb 1;76(3):535-47. doi: 10.1158/0008-5472.CAN-15-1389. Epub 2015 Oct 28. Cancer Res. 2016. PMID: 26511632 Free PMC article.

10

Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer.

Ebos JM, Quintela-Fandino M. Ebos JM, et al. Curr Drug Targets. 2016;17(15):1706. doi: 10.2174/1389450117999160425123635. Curr Drug Targets. 2016. PMID: 27109490 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters